Effect of 3-Fluorothalidomide and 3-Methylthalidomide Enantiomers on Tumor Necrosis Factor Production and Antitumor Responses to the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)

Oncology Research

Volumn 14, Issue 2, 2003, Pages 75-82

  Chung, Francisco ^a   Palmer, Brian D ^a   Muller, George W ^b   Man, Hon Wah ^b   Kestell, Phillip ^a   Baguley, Bruce C ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b CELGENE CORPORATION   (United States)

Author keywords

Antitumor; Colon 38; DMXAA; Enantiomers; Thalidomide; Tumor necrosis factor

Indexed keywords

3 FLUOROTHALIDOMIDE; 3 METHYLTHALIDOMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHIRAL CHROMATOGRAPHY; CHIRALITY; COLON TUMOR; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TUMOR LEVEL; ENANTIOMER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; MOUSE STRAIN; NONHUMAN; OPTICAL ROTATION; PRIORITY JOURNAL; RACEMIC MIXTURE; TUMOR GROWTH;

EID: 0842327350     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000003108748621     Document Type: Article

References (27)

1. Lenz, W. Malformations caused by drugs in pregnancy. Am. J. Dis. Child. 112:99-106; 1966.
2. Somers, G. Pharmacological properties of thalidomide, a new sedative drug. Br. J. Pharmacol. 15:111-116; 1960.
3. Sheskin, J. Further observation with thalidomide in lepra reactions. Leprosy Rev. 36:183-187; 1965.
4. Bousvaros, A.; Mueller, B. Thalidomide in gastrointestinal disorders. Drugs 61:777-787; 2001.
5. Ginsburg, P. M.; Hanan, I.; and Ehrenpreis, E. D. Treatment of sevcre esophageal Crohn's disease with thalidomide. Am. J. Gastroenterol. 96: 1305-1306; 2001.
6. Gutierrez-Rodriguez, O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. 27: 1118-1121; 1984.
7. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341:1565-1571; 1999.
8. Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21:16-19; 2003.
9. Sampaio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173:699-703; 1991.
10. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91:4082-4085; 1994.
11. Ching, L. M.; Xu, Z. F.; Gummer, B. H.; Palmer, B. D.; Joseph, W. R.; Baguley, B. C. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 72:339-343; 1995.
12. Philpott, M.; Baguley, B. C.; Ching, L. M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36:143-148; 1995.
13. Ching, L. M.; Browne, W. L.; Tchernegovski, R.; Gregory, T.; Baguley, B. C.; Palmer, B. D. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br. J. Cancer 78:336-343; 1998.
14. Cao, Z.; Joseph, W. R.; Browne, W. L.; Mountjoy, K. G.; Palmer, B. D.; Baguley, B. C.; Ching, L. M. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 80:716-723; 1999.
15. Kestell, P.; Zhao, L.; Baguley, B. C.; Palmer, B. D.; Muller, G.; Paxton, J. W.; Ching, L. M. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother. Pharmacol. 46:135-141; 2000.
16. Blaschke, G.; Kraft, H. P.; Fickentscher, K.; Kohler, F. Chromatographische Racemattreunnung von Thalidomid und teratogene Wirkung. Arzneimittelforschung 29:1640-1642; 1979.
17. Hoglund, P.; Eriksson, T.; Bjorkman, S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm. 26:363-383; 1998.
18. Fabro, S.; Smith, R. L.; Williams, R. T. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215: 296; 1967.
19. Eriksson, T.; Bjorkman, S.; Roth, B.; Fyge, A.; Hoglund, P. Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10:223-228; 1998.
20. Nishimura, K.; Hashimoto, Y.; Iwasaki, S. (S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: Implication of optical resolution of thalidomidal effects. Chem. Pharm. Bull. 42:1157-1159; 1994.
21. Miyachi, H.; Azuma, A.; Hioki, E.; Iwasaki, S.; Kobayashi, Y.; Hashimoto, Y. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem. Biophys. Res. Commun. 224:426-430; 1996.
22. Takeuchi, Y.; Shiragami, T.; Kimura, K.; Suzuki, E.; Shibata, N. (R)- and (S)-3-Fluorothalidomides: Isosteric analogues of thalidomide. Organic Lett. 1:1571-1573; 1999.
23. Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Boyd, M.; Thomsen, L. L.; Zhuang, L.; Denny, W. A. Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J. Med. Chem. 34:2864-2870; 1991.
24. Blaschke, G. a. G.; Wolfgang, F. Enantiomers of configurationally stable C-methylthalidomide. Liebigs Ann. Chemie 7:647-648; 1987.
25. Zhou, S.; Paxton, J. W.; Kestell, P.; Tingle, M. D.; Ching, L. M. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemother. Pharmacol. 47:319-326; 2001.
26. Keifer, J. A.; Guttridge, D. C.; Ashburner, B. P.; Baldwin, A. S., Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 276:22382-22387; 2001.
27. Woon, S. T.; Baguley, B.; Palmer, B.; Fraser, J.; Ching, L. M. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of the NF-κB in human tumour cell lines. Oncol. Res. 13: 95-101; 2002.